LIVER-R研究协议:对肝胆道癌症患者的杜尔瓦卢马布基疗法进行全球实践研究
Masafumi Ikeda1, Marcus-Alexander Wörns2, Mehmet Akce3
1Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Future oncology (London, England)
|November 24, 2025
概括
该LIVER-R研究将评估在现实环境中接受基于杜尔瓦卢马布的治疗的不可切除的肝细胞癌 (uHCC) 和晚期胆道癌 (aBTC) 患者的长期结果. 这项观察性研究旨在提供有关当前临床实践和治疗疗效的宝贵见解.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 肝胆道癌症 肝胆道癌症
背景情况:
- 基于杜尔瓦卢马布的疗法在临床试验中对不可切除的肝细胞癌 (uHCC) 和晚期胆道癌 (aBTC) 显示出希望.
- 现实世界的数据对于了解这些治疗方法的长期结果和临床实用性至关重要,超出试验环境.
研究的目的:
- 评估基于杜尔瓦卢马布的疗法在广泛,现实世界患者群体中的长期结果,包括HHCC和aBTC.
- 在常规临床实践中收集关于治疗模式,安全性和存活率的全面数据.
主要方法:
- LIVER-R研究 (NCT06252753) 是一项全球性的观察性研究,约有2500名成年患者参加.
- 数据收集包括基线信息和每六个月的随访,分析整体存活率,无进展存活率和安全性.
- 将使用Kaplan-Meier方法分析时间到事件的结果.
主要成果:
- 本节不适用,因为摘要描述了研究方案,尚未报告结果.
结论:
- 这项LIVER-R研究将为用杜尔瓦卢马布治疗的hhCC和aBTC患者产生大量,标准化,现实世界的数据集.
- 研究结果将为临床实践模式和不同患者群体中基于杜尔瓦卢马布的疗法的有效性提供关键的见解.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.9K
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.7K
相关概念视频
Bioavailability Study Design: Healthy Subjects Versus Patients
136
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
136
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
